Core Insights - Acadia Pharmaceuticals has a strong track record of exceeding earnings estimates, particularly in the last two quarters, with an average surprise of 50.00% [1] - The company reported earnings of $0.26 per share for the most recent quarter, surpassing the expected $0.14 per share by 85.71% [2] - For the previous quarter, Acadia's earnings were $0.16 per share against an estimate of $0.14 per share, resulting in a surprise of 14.29% [2] Earnings Estimates and Predictions - Recent estimates for Acadia have been increasing, with a positive Earnings ESP of +14.92%, indicating bullish sentiment among analysts regarding the company's earnings prospects [5][8] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a high likelihood of another earnings beat [8] - Historically, stocks with a positive Earnings ESP and a Zacks Rank of 3 or better have a nearly 70% chance of producing a positive surprise [6] Earnings ESP Explanation - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [7] - A positive Earnings ESP indicates that analysts have updated their estimates favorably just before the earnings release, which may lead to more accurate predictions [7] - A negative Earnings ESP can diminish the predictive power of the metric, but it does not necessarily indicate an earnings miss [8]

Core Viewpoint - Astronics Corporation (ATRO) is positioned well to potentially beat earnings estimates in its upcoming quarterly report, continuing a strong trend in the aerospace and defense equipment industry [1]. Earnings Performance - Astronics has a strong history of surpassing earnings estimates, averaging a 15.91% beat over the last two quarters [2]. - In the last reported quarter, Astronics achieved earnings of $0.49 per share, exceeding the Zacks Consensus Estimate of $0.42 per share by 16.67%. In the previous quarter, the company reported earnings of $0.38 per share against an expectation of $0.33 per share, resulting in a 15.15% surprise [3]. Earnings Estimates and Predictions - Recent estimates for Astronics have been increasing, with a positive Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat, especially given its favorable Zacks Rank [6]. - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [7]. - Astronics currently has an Earnings ESP of +4.75%, suggesting analysts are optimistic about the company's earnings prospects. This, combined with a Zacks Rank of 1 (Strong Buy), indicates a high probability of another earnings beat [9].

Core Insights - Check Point Software (CHKP) has a strong track record of exceeding earnings estimates, particularly in the last two quarters, with an average surprise of 30.62% [1] - In the last reported quarter, Check Point achieved earnings of $3.94 per share, significantly surpassing the Zacks Consensus Estimate of $2.45 per share by 60.82% [2] - The previous quarter also saw Check Point slightly exceed expectations, reporting earnings of $2.37 per share against an estimate of $2.36 per share, resulting in a surprise of 0.42% [2] Earnings Estimates and Predictions - There has been a favorable shift in earnings estimates for Check Point, with a positive Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat [5] - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have historically produced positive surprises nearly 70% of the time, suggesting a high probability of exceeding consensus estimates [6] - Check Point currently has an Earnings ESP of +0.08%, reflecting recent bullish sentiment among analysts regarding the company's earnings prospects [8] Upcoming Earnings Report - The next earnings report for Check Point is anticipated to be released on February 12, 2026, and the combination of a positive Earnings ESP and a Zacks Rank 3 suggests a potential for another earnings beat [8]

Core Insights - N-able (NABL) has consistently surpassed earnings estimates, averaging a 33.33% beat over the last two quarters [1] - The company reported earnings of $0.13 per share for the most recent quarter, exceeding the expected $0.09 per share by 44.44% [2] - For the previous quarter, N-able also beat estimates, reporting $0.11 per share against a consensus of $0.09, resulting in a 22.22% surprise [2] Earnings Estimates and Predictions - N-able's earnings estimates have been trending higher due to its history of earnings surprises, with a current Earnings ESP of +5.26% indicating bullish sentiment among analysts [5][8] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a strong likelihood of another earnings beat in the upcoming report [8] - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 or better have a nearly 70% chance of producing a positive surprise [6] Earnings ESP Explanation - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [7] - A negative Earnings ESP does not necessarily indicate an earnings miss but can reduce the predictive power of the metric [8] - It is crucial for investors to check a company's Earnings ESP prior to quarterly releases to enhance the likelihood of successful investment decisions [9]

Core Insights - Hagerty, Inc. (HGTY) has a strong track record of beating earnings estimates, with an average surprise of 31.31% over the last two quarters [1][2] Earnings Performance - For the last reported quarter, Hagerty achieved earnings of $0.13 per share, exceeding the Zacks Consensus Estimate of $0.09 per share, resulting in a surprise of 44.44% [2] - In the previous quarter, the company was expected to report earnings of $0.11 per share but delivered $0.13 per share, leading to a surprise of 18.18% [2] Earnings Estimates and Predictions - There has been a favorable change in earnings estimates for Hagerty, with a positive Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat [5] - The current Earnings ESP for Hagerty is +14.29%, suggesting that analysts are optimistic about the company's earnings prospects [8] - The combination of a positive Earnings ESP and a Zacks Rank of 2 (Buy) indicates a high probability of another earnings beat [8] Statistical Insights - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [6] - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [7]

Core Viewpoint - T. Rowe Price Group, Inc. (TROW) is expected to report an increase in both earnings and revenues for the fourth quarter of 2025 compared to the previous year, despite facing challenges such as net outflows and rising expenses [1][7]. Financial Performance - In the last reported quarter, TROW's earnings exceeded the Zacks Consensus Estimate, driven by higher assets under management (AUM) and increased investment advisory fees, although higher expenses negatively impacted results [2][6]. - The consensus estimate for fourth-quarter earnings is $2.46 per share, reflecting a year-over-year increase of 16%, while revenues are estimated at $1.92 billion, indicating a 5.1% rise from the prior year [8][9]. Assets Under Management - TROW's preliminary AUM as of December 31, 2025, is $1.78 trillion, showing a slight increase from September 30, 2025, supported by improved performance in fixed income, multi-asset, and alternative products [4][5]. - The Zacks Consensus Estimate for total AUM is also pegged at $1.78 trillion, indicating a marginal sequential increase [5]. Market Conditions - The S&P 500 Index gained approximately 3.1% during the October-December quarter, suggesting moderate market performance, which likely benefited TROW through steady fixed-income inflows and stable equity market returns [3]. Net Outflows and Expenses - TROW experienced net outflows of $11.6 billion for the quarter ended December 31, 2025, amid a challenging operating environment [4]. - The company continues to incur significant expenses to attract new clients and invest in technology and employee compensation, which is expected to have increased overall expenses for the quarter [6].

Core Insights - Lightspeed Commerce (LSPD) is set to announce its third-quarter fiscal 2026 results on February 5, with earnings estimated at 12 cents per share and revenues projected at $311.63 million, reflecting an 11.25% year-over-year increase [1][8] Group 1: Performance Expectations - The fiscal third-quarter performance is expected to benefit from positive operating trends and strategic transformation efforts, including an expanded outbound sales organization and improved software average revenue per user [3][8] - Transaction-based revenue growth is anticipated due to sustained payments penetration, especially in international markets, and the introduction of the Tempo solution for restaurant operators is expected to enhance operational efficiency in European hospitality [4][8] Group 2: Challenges Ahead - Seasonal weakness in European hospitality and golf operations during winter months is expected to negatively impact performance, with reduced customer traffic affecting gross transaction value and same-store sales [5] - Software revenue growth may moderate as the company cycles through previous price increases, and shifts in geographic and vertical mix could pressure overall growth rates compared to the strong fiscal second quarter [5] Group 3: Earnings Model Insights - According to the Zacks model, the current Earnings ESP for Lightspeed is 0.00% with a Zacks Rank of 3, indicating that the odds of an earnings beat are not favorable at this time [6]

Key Takeaways NWSA to report Q2 results on Feb. 5, with consensus revenues of $2.31B, implying a 3.21% year-over-year gain.NWSA's EPS estimate is 33 cents, unchanged year over year, pointing to limited bottom-line expansion.NWSA's Book Publishing was expected to rebound, while digital revenues at 62% of sales offset softness.News Corporation (NWSA) is scheduled to report second-quarter fiscal 2026 results on Feb. 5.The Zacks Consensus Estimate for revenues is pegged at $2.31 billion, indicating growth of 3. ...

Key Takeaways AMCR will report Q2 FY26 results on Feb. 3, with revenues seen at $5.55B and earnings of 83 cents per share.AMCR's outlook reflects a major revenue boost from the Berry Global merger, offsetting volume pressure.AMCR's segments face volume declines, cushioned by price/mix gains, currency benefits and acquisitions.Amcor Plc (AMCR) is scheduled to report second-quarter fiscal 2026 results on Feb. 3, after the closing bell.The Zacks Consensus Estimate for AMCR’s fiscal second-quarter revenues is p ...

Core Viewpoint - AbbVie is expected to report fourth-quarter and full-year 2025 earnings on February 4, with sales projected at $16.36 billion and earnings per share (EPS) at $2.66, although EPS estimates for 2025 and 2026 have declined recently [2][6]. Earnings Performance - AbbVie has consistently exceeded earnings expectations in the past four quarters, with an average earnings surprise of 3.05%, including a 5.08% surprise in the last quarter [4][6]. Revenue Drivers - The anticipated revenue growth for AbbVie in Q4 2025 is primarily driven by increased sales of newer immunology drugs, Skyrizi and Rinvoq, as sales of the flagship drug Humira continue to decline due to biosimilar competition [9][10]. - The Zacks Consensus Estimate for Skyrizi sales is $4.91 billion, while Rinvoq is estimated at $2.39 billion [9]. Sales Estimates - Humira's sales are projected at $949 million, reflecting ongoing erosion from biosimilars, while Imbruvica sales are expected to decline to $715 million due to competition [10]. - Sales for Roche-partnered Venclexta are estimated to rise to $725 million, driven by strong demand [11]. - Neuroscience product sales are expected to reach approximately $3.00 billion, supported by strong performances from Botox Therapeutic, Vraylar, and new migraine drugs [12]. - Aesthetics product sales are projected at $1.28 billion, showing signs of recovery from previous sluggishness [13]. Valuation and Market Position - AbbVie shares are currently trading at a P/E ratio of 15.38, below the industry average of 18.42, indicating a discount relative to peers [17]. - Despite underperforming the industry over the past year, AbbVie is expected to achieve robust revenue growth driven by its newer drug launches [19]. Future Outlook - AbbVie anticipates a high single-digit revenue compound annual growth rate (CAGR) through 2029, supported by the successful launches of Skyrizi and Rinvoq [19]. - The company continues to invest in its pipeline through strategic collaborations, including a recent licensing deal with RemeGen for a bispecific antibody candidate [21]. - A favorable valuation and strong earnings growth expectations provide a compelling case for long-term investment in AbbVie stock [22].